Tratamiento para tuberculosis resistente a rifampicina o multirresistente: análisis comparativo de indicadores programáticos entre Buenaventura y otros municipios del Valle del Cauca, Colombia / Treatment for multidrug-resistant tuberculosis: A comparative analysis of programmatic outcome indicators between Buenaventura and other municipalities of Valle del Cauca, Colombia

Resumen Introducción. El manejo adecuado de la tuberculosis multirresistente es una estrategia priorizada para el control de la tuberculosis en el mundo. Objetivo. Evaluar las diferencias entre las características demográficas y clínicas, y los indicadores programáticos de los pacientes con diagnóstico confirmado de tuberculosis pulmonar resistente a rifampicina o multirresistente en Buenaventura, frente a la cohorte de los demás municipios del Valle del Cauca entre 2013 y 2016. Materiales y métodos. Se desarrolló un estudio analítico de cohortes para comparar los registros de pacientes mayores de 15 años con tuberculosis multirresistente, del Programa de Tuberculosis de Buenaventura (con ácido paraaminosalicílico), frente a los demás municipios del Valle del Cauca (sin ácido paraaminosalicílico). Resultados. Se registraron 99 casos con una mediana de edad de 40 años (RIC = 26 - 53); en Buenaventura, el 56 % eran mujeres; en los demás municipios, predominaron los hombres (67 %); el 95 % de los evaluados tenía aseguramiento en salud. La comorbilidad más frecuente fue diabetes (14 %). Las reacciones adversas a medicamentos antituberculosos en Buenaventura fueron 1,3 veces más frecuentes que en los demás municipios (OR = 2,3; IC95 %: 0,993 - 5,568; p = 0,04). En Buenaventura falleció el 5 % de los casos frente al 15 % reportado en los demás municipios. No hubo fracasos con el tratamiento en Buenaventura, pero se reportó un 35 % de pérdida del seguimiento. El éxito del tratamiento fue mayor en Buenaventura en el 56 %. Conclusión. El programa fortalecido de Buenaventura presentó mejores resultados programáticos que los demás municipios del Valle del Cauca. El acceso a pruebas moleculares, la disponibilidad de tratamientos acortados y el seguimiento continuo para identificar reacciones adversas a medicamentos antituberculosos son un derrotero para todos los programas de control.

Abstract Introduction. Proper management of multidrug-resistant tuberculosis is a prioritized strategy for tuberculosis control worldwide. Objective. To evaluate differences concerning demographic and clinical characteristics and programmatic indicators of Buenaventura patient cohort with confirmed diagnosis of multidrug-resistant tuberculosis, compared to those of the other municipalities from Valle del Cauca, Colombia, 2013-2016. Materials and methods. We conducted an analytical cohort study to compare records of patients older than 15 years with multidrug-resistant tuberculosis included in the Programa de Tuberculosis de Buenaventura (with para-aminosalicylic acid) versus the other municipalities of Valle del Cauca (without para-aminosalicylic). Results. Ninety-nine cases were recorded with a median age of 40 years (IQR = 26 - 53); in Buenaventura, 56% of the patients were women, while in the other municipalities, men predominated with 67%; 95% had health insurance. The most common comorbidity was diabetes (14%). Adverse reactions to antituberculosis medications in Buenaventura were 1.3 times more frequent than in the other municipalities (OR = 2.3; 95% CI = 0.993 - 5.568; p = 0.04). In Buenaventura, the mortality rate was 5% compared to the 15% reported in the other municipalities. Treatment failures were not reported in Buenaventura, but 35% did not continue with the follow-up. Treatment success was higher in Buenaventura (56 %). Conclusion. A strengthened program in Buenaventura presented better programmatic results than those from the other municipalities of Valle del Cauca. Access to molecular tests, availability of shortened treatments, and continuous monitoring to identify adverse reactions to antituberculosis medications are routes for all other control programs.

Actualización en la detección de la tuberculosis a través de pruebas moleculares / An update on the detection of tuberculosis through molecular testing

La tuberculosis es una enfermedad infecciosa respiratoria que afecta a un tercio de la población mundial y es una amenaza significativa para la salud global. La detección de la tuberculosis de manera temprana es crucial para un tratamiento eficaz y prevenir su propagación. Una solución para mejorar el diagnóstico y abordar la resistencia a los medicamentos antituberculosos es el uso de pruebas moleculares de alto rendimiento para la identificación del Mycobacterium tuberculosis y su susceptibilidad. Este estudio de revisión narrativa busca describir las generalidades, la eficacia, la sensibilidad, las ventajas y las limitaciones de las principales pruebas moleculares; Truenat® MTB, MTB plus y MTB-RIF, Abbott RealTime MTB y MTB RIF/INH en el sistema m2000sp y m2000rt y FluoroType MTBDR, además, de compararlas con GeneXpert MTB/RIF o Xpert Ultra, utilizadas para la detección del patógeno resistente a medicamentos tuberculosos. Estas pruebas utilizan diversas técnicas para la detección del ADN del Mycobacterium tuberculosis y la cuantificación de la carga bacteriana con alta sensibilidad y especificidad, resultados rápidos, reducción de los errores humanos, así como la detección temprana de cepas drogo-resistentes. A pesar de que requieren infraestructura especializada y competencias profesionales para su implementación, representan avances significativos con el potencial de mejorar la atención sanitaria y la gestión de la tuberculosis. Estas pruebas moleculares, comparadas con el GeneXpert, son una alternativa viable, aunque esta última tecnología sigue siendo la preferida en áreas con recursos limitados

Tuberculosis is a respiratory infectious disease that affects one third of the world's population and is a significant threat to global health. Detecting tuberculosis early is crucial for effective treatment and preventing its spread. One solution to improve diagnosis and address antituberculosis drug resistance is the use of high-throughput molecular tests for the identification of Mycobacterium tuberculosis and its susceptibility. This narrative review study seeks to describe the generalities, efficacy, sensitivity, advantages and limitations of the main molecular tests: Truenat® MTB, MTB plus and MTB-RIF, Abbott RealTime MTB and MTB RIF/INH on the m2000sp and m2000rt system and FluoroType MTBDR, and to compare them with GeneXpert MTB/RIF or Xpert Ultra, used for the detection of the tuberculosis drug-resistant pathogen. These tests use various techniques for the detection of Mycobacterium tuberculosis DNA and quantification of bacterial load with high sensitivity and specificity, rapid results, reduction of human error, as well as early detection of drug-resistant strains

Tuberculosis: a narrative review on epidemiology, risks, implications, preventions and treatments

Tuberculosis (TB) is an airborne disease that generally affects the pulmonary portion of the human body leading to severe coughing, fever and chest pain. It is caused by a bacterium known as Mycobacterium tuberculosis, which kills human beings each and every year globally more than the death toll of combined HIV and malaria. However, it is preventable, treatable, and curable. The world is suffering due to this dreaded disease with an approximate number of 11 million TB cases and 1.6 million deaths annually. Tuberculosis increases the public health attention because of its high mortality rates after HIV/AIDS. World Health Organisation (WHO) and Centre for Chronic Disease Control (CCDC) are the leading organizations playing an important role to combat against TB by publishing proper health guidelines and treatments through reliable awareness campaigns whenever there is sudden outbreaks of TB, COVID-19 and related diseases. A wide range of research findings, clinical reports and new treatment methods like multi-drug therapy have been developed to combat TB. It is still necessary to develop new research and innovative ideas and proper implementations of the treatment and prevention guidelines of WHO and CCDC to fight against this fatal disease. In countries having higher increase of populations due to immunosuppressed chronic diseases like HIV, diabetes and pandemics like COVID-19, eradication of TB infection is a very difficult and challenging task. This mini review is based on the critical analyses of the data available from the official websites of WHO (Global Tuberculosis Report), CCDC, and search engines like Medline, PubMed, Google Scholar, and research findings of selected articles, textbooks were used as additional sources which are cited in the reference section.

Sputum positivity status for acid fast bacilli in patient attending a designated microscopy centre of a tertiary care hospital, Lucknow

Background: Tuberculosis is a contagious bacterial disease that is considered to be one of the deadliest diseases worldwide. It affects lungs and causes pulmonary TB. Today in India, every minute 3 to 4 people die of TB, more than 1000 die every day and more than 5 lakhs die every year. Demonstration of AFB in smear has a great important in control of TB, as smear positivity directly correlates with infectivity. Methods: It was a cross-sectional study. It lasted over a period of 6 months (January to June). Samples were collected from patients attending TB and Chest OPD of IIMS&R Hospital and sent for AFB examination by Ziehl-Neelsen (ZN) microscopy at microbiology lab. Patients with symptom of cough lasting for more than 2 weeks were included. Results: Out of 718 patient’s samples, 128 were smear positive by ZN staining method. Out of which 81 (63.28%) were males and 47 (36.72%) were females. According to age distribution 35 (27.35%) were <30 years of age, 68 (53.12%) were in between 30 and 60 while 25 (19.53%) were >60 years of age. 105 (82.03%) positive patients were found to be from rural area and remaining 23 (17.9%) patients belong to urban area. 29 patients were found to have a past history of TB of 1 year. Out of 128 positive patients none were smokers. 25 (19.53%) were tobacco chewers. 11 (8.56%) were contact with a case of TB. Conclusions: Demonstration of AFB in smear has a great important in control of TB, as smear positivity directly correlates with infectivity. Z-N staining method is the most commonly used worldwide.

Innovative Hybrid Compounds Targeting Tuberculosis: Development, Characterization and Bioefficacy analysis of 6-substituted-2-Chloroquinoline-3-Carbaldehyde Hydrazide Ester derivatives

This study delves into the biological activity of ester compounds obtained from analogues of 6-substituted-2-chloroquinoline-3-carbaldehyde hydrazide, aiming to exploit the combined antitubercular properties of quinoline and hydrazide to create innovative hybrid compounds. The molecules underwent a meticulous multi-step synthesis process, followed by purification through recrystallization. Methodologies such as 1H NMR, 13C NMR, FTIR and Mass Spectrometry was used to confirm the molecular structures of developed derivatives. SWISSADME, an online tool, was utilized to predict the ADME properties, shedding light on their pharmacokinetic profiles. Evaluation of in vitro antitubercular activity employing the Alamar blue method highlighted compounds 4a and 4f, exhibiting noteworthy efficacy achieving threshold concentrations of 6.25 µg/ml for M. tuberculosis inhibition. These findings suggest the possibility of novel quinoline Scaffold as potential molecule for TB treatment, contributing to ongoing endeavors in TB drug discovery and potentially laying the groundwork to develop effective antitubercular therapies.

Pulmonary and Extrapulmonary Tuberculosis, An Inflammatory Disease misdiagnosed as Cancer

Introduction:Tuberculosis is a serious infection associated with a high mortality rate if not treated.The clinical and imaging presentation are usually nonspecific and can mimic malignancy; therefore, extrapulmonary TB should be considered in the differential diagnosis of any suspicious extrapulmonary masses, particularly in immunocompromised patients. Objective:This study aims to analyse 160 cases of pulmonary and extra-pulmonary tuberculosis correlate the pathological features with the clinical data and find the most common differentiation diagnosis of both pulmonary and extrapulmonary tuberculosis.Methodology: A retrospective analysis of 160 cases of pulmonary and extra-pulmonary tuberculosis was performed.The age, gender , site, and symptoms of the lesion were collected, extrapulmonary sites were detected including rare and unusual sites and the differential diagnosis of these lesions was highlighted. The data were plotted in graphs and were analyzed.Result: In our study 63.6% were male and 36.4 were females.The majority of the patients were in the age group of 21-30 years followed by 31- 40 years, cough and hemoptysis were the most common symptoms followed by cervical swelling with 39% and 33% respectively. The most common sites were lung with (39%) and cervical swelling with (33%).The main differential diagnosis for many pulmonary and all extra-pulmonary tuberculosis was malignancy. Conclusion:Tuberculosis is a serious young person's disease that can affect almost every organ and tissue of the body and should be considered in the differential diagnosis of suspicious masses, as tuberculosis is often misdiagnosed as cancer.

Tuberculosis extrapulmonar, la gran simuladora / Extrapulmonary tuberculosis, the great pretender

La tuberculosis es una enfermedad infecciosa considerada un problema de salud pública ya que constituye una de las principales causas de morbimortalidad a nivel mundial; su forma clínica más frecuente es la tuberculosis pulmonar, sin embargo, esta enfermedad también puede afectar estructuras extrapulmonares cuyo diagnóstico generalmente es tardío debido a que los síntomas y signos son inespecíficos. En este artículo se presenta un caso clínico de tuberculosis extrapulmonar (miliar, sistema nervioso central e intestinal) en el Hospital Universitario de Puebla (AU)

Tuberculosis is an infectious disease considered a public health problem since it is one of the main causes of morbidity and mortality worldwide; the most common clinical form is pulmonary tuberculosis; however, this disease can also affect extrapulmonary structures whose diagnosis is generally late because the symptoms and signs are nonspecific. This article presents a clinical case of extrapulmonary tuberculosis (miliary, central nervous system and intestinal) at the University Hospital of Puebla (AU)

Síndrome medular completo secundario a mielitis infecciosa causada por Mycobacterium tuberculosis. Informe de caso / Central spinal cord syndrome secondary to infectious myelitis caused by Mycobacterium Tuberculosis

Introducción: La tuberculosis, un problema de salud pública a nivel mundial que afecta a la población. Causada por Mycobacterium tuberculosis, se transmite a través de gotas de saliva y la presentación extrapulmonar afecta 5­45% de la población infectada. La tuberculosis de columna vertebral es una enfermedad crónica y progresiva, secundaria a la diseminación de un foco primario, que puede pasar desapercibido. Descripción del caso: Paciente masculino con fiebre de 4 días de evolución, nocturna, con diaforesis, debilidad de fuerza de miembros superiores e inferiores bilateral; miembros inferiores con (0) fuerza y miembros superiores (1), ausencia de reflejos osteotendinosos en ambas extremidades, nivel sensitivo C4, con ausencia de control de esfínteres. El diagnóstico se estableció mediante toracocentesis diagnóstica, realizando GeneXpert y cultivo de líquido pleural, positivo para tuberculosis y negativo para micobacteria resistente; resonancia magnética con gadolinio identifica área hiperintensa cervical medular de C2 hasta C4, produciendo aumento en el diámetro de la médula espinal. Se inició tratamiento tetraconjugado: isoniazida, rifampicina, pirazinamida y etambutol. Cuatro semanas posteriores al comienzo de tratamiento paciente presenta (2) fuerza en miembros inferiores y (3) en miembros superiores, continuando con terapia física. Conclusión: la tuberculosis se presenta de maneras muy diversas y se debe tener presente en pacientes jóvenes sin antecedentes personales patológicos que presenten cuadros de fiebre como uno de los primeros síntomas. Pruebas diagnósticas serológicas, GeneXpert y de imagen como la resonancia magnética ayudan en establecer un diagnóstico. La tuberculosis debe considerarse siempre en un proceso infeccioso que se desconoce etiología...(AU)

Utilidad de GeneXpert MTB/RIF en el diagnóstico de tuberculosis frente a la baciloscopia / Utility of GeneXpert MTB/RIF in the Diagnosis of Tuberculosis Compared to Sputum Smear Microscopy

Introducción: La implementación de un método diagnóstico adecuado y eficiente es crucial para la detección temprana de la tuberculosis. Esto no solo permite un control efectivo de la enfermedad para evitar su transmisión y progresión hacia estadios más graves, además previene el desarrollo de resistencia a los fármacos en los pacientes.Objetivo: Evaluar la utilidad de la prueba molecular GeneXpert MTB/RIF en el diag-nóstico de Mycobacterium tuberculosis complex, en comparación con la bacilos-copia, utilizando el cultivo como referencia.Material y Métodos: Se realizó un estudio descriptivo, observacional y no expe-rimental de corte transversal, se incluyeron 253 muestras de pacientes de ambos sexos y de variados rangos de edad, que fueron evaluadas mediante baciloscopia, GeneXpert MTB/RIF y cultivo. El estudio se centró en muestras procesadas en un Hospital público de la ciudad de Quito durante el período de enero de 2021 a mayo de 2022Resultados: La prueba molecular GeneXpert MTB/RIF mostró una sensibilidad del 94,7% y una especificidad del 93,9% para el diagnóstico de Mycobacterium tu-berculosis complex. Además, se identificó un caso de resistencia a la rifampicina.Conclusión: Este estudio confirma la eficacia de la prueba molecular GeneXpert MTB/RIF sobre la baciloscopia para el diagnóstico oportuno de Mycobacterium tu-berculosis complex. Sin embargo, es esencial considerar las diversas condiciones de las muestras y pacientes para optimizar la precisión diagnóstica

Introduction: Implementing an appropriate and efficient diagnostic method is cru-cial for the early detection of tuberculosis. This not only allows for effective control of the disease to prevent its transmission and progression to more severe stages but also prevents the development of drug resistance in patients.Objective: To evaluate the utility of the GeneXpert MTB/RIF molecular test in diag-nosing Mycobacterium tuberculosis complex, compared to sputum smear micros-copy, using culture as the reference. Material and Methods: A descriptive, observational, and non-experimental cross-sectional study was conducted, including 253 samples from patients of both sexes and various age ranges, which were assessed using sputum smear micros-copy, GeneXpert MTB/RIF, and culture. The study focused on samples processed at a Quito ́s Public Hospital during the period from January 2021 to May 2022.Results: The GeneXpert MTB/RIF molecular test showed a sensitivity of 94.7% and a specificity of 93.9% for the diagnosis of Mycobacterium tuberculosis com-plex. Additionally, a case of resistance to rifampicin was identified.Conclusion: This study confirms the effectiveness of the GeneXpert MTB/RIF mo-lecular test over sputum smear microscopy for the timely diagnosis of tuberculosis. However, it is essential to consider the diverse conditions of the samples and pa-tients to optimize diagnostic accuracy

A case of abdominal tuberculosis presenting as obstructive jaundice

Extrapulmonary tuberculosis is notorious for its many manifestations, which can lead to delayed diagnosis and treatment. In particular, abdominal tuberculosis is easily overlooked because the incidence is low and because it can mimic common non-infectious abdominal syndromes. We describe here a 45-year-old female presenting with obstructive jaundice. In this patient, a pancreatic mass was found and tuberculosis was first diagnosed after a diagnostic laparoscopic. Tuberculosis should be included in the differential diagnosis of intra-abdominal mass lesions, especially in persons originating from regions where tuberculosis is endemic. Invasive procedures are often required to obtain adequate diagnostic samples.

Tuberculosis abdominal en pediatría: presentación de un caso / Abdominal tuberculosis in pediatrics: A case report

La tuberculosis es una enfermedad infectocontagiosa cuya forma de presentación más frecuente es la pulmonar; la afectación abdominal es poco frecuente, por lo que su diagnóstico continúa siendo un desafío. Las manifestaciones clínicas de la tuberculosis abdominal así como sus hallazgos en el examen físico suelen ser inespecíficos y, en muchas ocasiones, similares a los de otras patologías, por lo que es fundamental considerarla entre los diagnósticos diferenciales. Se presenta el caso clínico de un paciente de sexo masculino, de 15 años de edad, hospitalizado por un síndrome febril prolongado asociado a dolor abdominal, diarrea, sudoración nocturna y pérdida de peso

Tuberculosis is an infectious disease which most commonly compromises the respiratory system, whereas abdominal involvement is rare, thus its diagnosis is a challenge. The clinical manifestations of abdominal tuberculosis as well as its physical examination findings are usually non-specific and, frequently, similar to those of other diseases, so it is critical to consider abdominal tuberculosis among the differential diagnoses. Here we report the clinical case of a 15-year-old male patient hospitalized for a prolonged febrile syndrome associated with abdominal pain, diarrhea, night sweats, and weight loss.

Mycobacterium tuberculosis y virus linfotrópico humano, una co-infección fatal / Mycobacterium tuberculosis and human lymphotropic virus, a fatal co-infection

La tuberculosis es una infección de alta incidencia en Latinoamérica. Su presentación como infección activa está determinada por factores de riesgo del hospedero. Comunicamos el caso clínico de una mujer joven que presentó una forma grave de tuberculosis pulmonar. Al explorar sus factores de riesgo se confirmó un estado de inmunosupresión profundo, causado por un linfoma de células T, asociada a una co-infección por virus linfotrópico T humano tipo 1. Se destacan los aspectos microbiológicos y de pronóstico de la co-infección de Mycobacterium tuberculosis y HTLV-1

Tuberculosis is a high-incidence infection in Latin America. Its presentation as an active infection is determined by risk factors in the host. We report the case of a young woman who presented a severe form of pulmonary tuberculosis. When exploring her risk factors, a profound state of immunosuppression was found, caused by T-cell lymphoma, associated with co-infection with human lymphotropic virus. Microbiological and prognostic aspects of Mycobacterium tuberculosis and HTLV-1 co-infection are highlighted.

Mycobacterium tuberculosis resistente a Rifampicina en la provincia de El Oro-Ecuador / Rifampicin-resistant mycobacterium tuberculosis in the province of Oro-Ecuador / Mycobacterium tuberculosis resistente à Rifampicina na província de Oro-Equador

Introducción. La tuberculosis es una de las enfermedades infecciosas más antiguas y comunes, causada por una bacteria en forma de bastón, o bacilo, llamada Mycobacterium tuberculosis. Esta enfermedad es tratable con antibióticos, los cuales se prescriben durante meses debido a la lenta tasa de crecimiento de las bacterias. Entre los fármacos utilizados la Rifampicina se utiliza terapéuticamente para combatir esta enfermedad, sin embargo, algunos pacientes pueden presentar o desarrollar resistencia a este antibiótico, por lo que, es importante completar el tratamiento para evitar el desarrollo de bacterias farmacorresistentes y la re ocurrencia de la enfermedad. Objetivo. Caracterizar el Mycobacterium tuberculosis resistente a Rifampicina en la provincia de El Oro. Materiales y métodos. Se realizó un estudio con un enfoque cuantitativo, de tipo descriptivo y no experimental. La muestra se obtuvo de la base de datos del laboratorio clínico del área de micobacterias del Hospital Teófilo Dávila en el período 2019 - 2022, quienes luego de aplicar la prueba molecular rápida GeneXpert MTB/RIF o ULTRA determinaron que 48 pacientes presentaron resistencia a la Rifampicina en el tratamiento de la Mycobacterium tuberculosis. Resultados. El reporte del laboratorio evidenció que en el año 2022 se estableció el mayor número de casos de resistencia a Rifampicina para el tratamiento de Mycobacterium tuberculosis, alcanzando el 33,3%; el grupo etario de mayor afectación fue el adulto joven (20 a 49 años) con un 52,1%, y con una frecuencia elevada de 66,7% el sexo masculino. La comorbilidad con mayor predominio estuvo en los pacientes diagnosticados Diabetes Mellitus tipo 2 con un 27,1% y la condición de ingreso de pacientes con resistencia a Rifampicina, son de nuevos casos con 75%. Conclusiones. En la provincia de El Oro, entre el año 2019 - 2022 se presentaron 48 casos resistentes al antibiótico Rifampicina en el tratamiento de la TB, entre ellos el 75% corresponden a una resistencia inicial, es decir, pacientes que no fueron tratados contra la enfermedad, el otro 25% engloba a aquellos pacientes que recayeron en la enfermedad, fracaso o perdida de seguimiento por parte del laboratorio de vigilancia, área de micobacterias del Hospital Teófilo Dávila.

Introduction. Tuberculosis is one of the oldest and most common infectious diseases, caused by a rod-shaped bacterium, or bacillus, called Mycobacterium tuberculosis. This disease is treatable with antibiotics, which are prescribed for months due to the slow growth rate of the bacteria. Among the drugs used, Rifampicin is used therapeutically to combat this disease, however, some patients may present or develop resistance to this antibiotic, therefore, it is important to complete the treatment to avoid the development of drug-resistant bacteria and the reoccurrence of the disease. Objective. To characterize the Mycobacterium tuberculosis resistant to Rifampicin in the province of El Oro. Materials and methods. A quantitative, descriptive and non-experimental study was carried out. The sample was obtained from the database of the clinical laboratory of the mycobacteria area of the Teófilo Dávila Hospital in the period 2019 - 2022, who after applying the rapid molecular test GeneXpert MTB/RIF or ULTRA determined that 48 patients presented resistance to Rifampicin in the treatment of Mycobacterium tuberculosis. Results. The laboratory report showed that in the year 2022 the highest number of cases of resistance to Rifampicin for the treatment of Mycobacterium tuberculosis was established, reaching 33.3%; the age group most affected was young adults (20 to 49 years) with 52.1%, and with a high frequency of 66.7% in the male sex. The most prevalent comorbidity was in patients diagnosed with Diabetes Mellitus type 2 with 27.1% and the condition of admission of patients with resistance to Rifampicin, are new cases with 75%. Conclusions. In the province of El Oro, between 2019 - 2022 there were 48 cases resistant to the antibiotic Rifampicin in the treatment of TB, among them 75% correspond to an initial resistance, that is, patients who were not treated against the disease, the other 25% encompasses those patients who relapsed in the disease, failure or loss of follow-up by the surveillance laboratory, mycobacteria area of the Teófilo Dávila Hospital.

Introdução. A tuberculose é uma das doenças infecciosas mais antigas e mais comuns, causada por uma bactéria em forma de bastonete, ou bacilo, chamada Mycobacterium tuberculosis. A doença pode ser tratada com antibióticos, que são prescritos por meses devido à lenta taxa de crescimento da bactéria. Entre os medicamentos utilizados, a rifampicina é usada terapeuticamente para combater essa doença; no entanto, alguns pacientes podem desenvolver resistência a esse antibiótico, por isso é importante concluir o tratamento para evitar o desenvolvimento de bactérias resistentes aos medicamentos e a recorrência da doença. Objetivo. Caracterizar o Mycobacterium tuberculosis resistente à rifampicina na província de El Oro. Materiais e métodos. Foi realizado um estudo quantitativo, descritivo e não experimental. A amostra foi obtida do banco de dados do laboratório clínico da área de micobactérias do Hospital Teófilo Dávila no período de 2019 a 2022, que, após aplicar o teste molecular rápido GeneXpert MTB/RIF ou ULTRA, determinou que 48 pacientes apresentavam resistência à rifampicina no tratamento de Mycobacterium tuberculosis. Resultados. O laudo laboratorial demonstrou que o maior número de casos de resistência à Rifampicina para o tratamento do Mycobacterium tuberculosis se estabeleceu em 2022, atingindo 33,3%; a faixa etária mais afetada foi a de adultos jovens (20-49 anos) com 52,1%, e com alta frequência de 66,7% no sexo masculino. A comorbidade mais prevalente foi em pacientes diagnosticados com Diabetes Mellitus tipo 2 com 27,1% e a condição de admissão de pacientes com resistência à Rifampicina, são casos novos com 75%. Conclusões. Na província de El Oro, entre 2019 e 2022, houve 48 casos resistentes ao antibiótico Rifampicina no tratamento da TB, entre eles 75% correspondem a uma resistência inicial, ou seja, pacientes que não foram tratados contra a doença, os outros 25% incluem aqueles pacientes que recaíram na doença, falha ou perda de monitoramento pelo laboratório de vigilância, área de micobactérias do Hospital Teófilo Dávila.

Atypical presentation of breast tuberculosis: a case report

Breast tuberculosis is a rare disease even in endemic regions. It often presents in young females as a breast lump and is confused with other benign and malignant lesions. We presented a case of 47-year-old woman, initially diagnosed with a breast carcinoma based on clinical examination and radiological imaging. However, breast biopsy with histopathological analysis revealed breast tuberculosis. Anti-tubercular chemotherapy was used during six months with good evolution. Given low specificity of clinical and radiological findings of mammary tuberculosis, histopathological study of any breast nodule is mandatory to exclude this rare entity and avoid unnecessary surgical procedure.

Plasma cytokine levels as markers of pathogenesis and treatment response in patients with non-tuberculous mycobacterial pulmonary disease

We investigated the value of plasma cytokine levels as markers of pathogenesis and treatment response in patients with non-tuberculous mycobacteria (NTM) pulmonary disease. Plasma cytokine levels were measured and compared among patients with NTM pulmonary disease (n=111), tuberculosis (TB) patients (n=50), and healthy individuals (n=40). Changes during treatment were monitored at 3 and 6 months after treatment. According to the treatment response, NTM patients were classified as 'resistance' or 'sensitivity' responders. The results revealed that five out of twelve cytokines exhibited significantly higher levels in NTM patients compared to controls. Among these, interleukin (IL)-6 demonstrated the strongest discriminating capacity for NTM. Furthermore, when combined with IL-1β, they efficiently distinguished between NTM drug-resistant and drug-sensitive patients, as well as between NTM and TB groups. Additionally, IL-6 levels initially rose and then decreased in the NTM drug-resistant group during the six months of treatment, similar to the behavior of IL-1β in the NTM drug-sensitive group. Subgroup analyses of the sensitive group with differential treatment responses revealed an increase in IL-10 levels in the six-month treatment responders. A high IL-6/IL-10 ratio was associated with increased disease severity of NTM and TB. Collectively, combinations of various plasma cytokines, specifically IL-1β, IL-6, and IL-10, effectively distinguished NTM patients with varying mycobacterial burdens, with IL-6 and IL-10 emerging as potential biomarkers for early treatment response. The combination of IL-6 and IL-1β demonstrated the highest discriminatory value for distinguishing between NTM-resistant and NTM-sensitive groups as well as between NTM and TB groups.

Ag85B with c-di-AMP as mucosal adjuvant showed immunotherapeutic effects on persistent Mycobacterium tuberculosis infection in mice

Tuberculosis (TB), caused by Mycobacterium tuberculosis, remains the leading cause of mortality by a single infectious agent in the world. M. tuberculosis infection could also result in clinical chronic infection, known as latent TB infection (LTBI). Compared to the current limited treatment, several subunit vaccines showed immunotherapeutic effects and were included in clinical trials. In this study, a subunit vaccine of Ag85B with a novel mucosal adjuvant c-di-AMP (Ag85B:c-di-AMP) was delivered intranasally to a persistent M. tuberculosis H37Ra infection mouse model, which also presented the asymptomatic characteristics of LTBI. Compared with Ag85B immunization, Ag85B:c-di-AMP vaccination induced stronger humoral immune responses, significantly higher CD4+ T cells recruitment, enhanced Th1/Th2/Th17 profile response in the lung, decreased pathological lesions of the lung, and reduced M. tuberculosis load in mice. Taken together, Ag85B:c-di-AMP mucosal route immunization provided an immunotherapeutic effect on persistent M. tuberculosis H37Ra infection, and c-di-AMP, as a promising potential mucosal adjuvant, could be further used in therapeutic or prophylactic vaccine strategies for persistent M. tuberculosis infection as well as LTBI.

Masa nasal como único compromiso extrapulmonar de infección por M. Tuberculosis / Nasal mass as the only extrapulmonary compromise of M. Tuberculosis infection / Massa nasal como único compromisso extrapulmonar da infecção por M. Tuberculose

La tuberculosis aún es un problema de salud pública mundial. La infección causada por Mycobacterium tuberculosis se manifiesta de forma principal a nivel pulmonar. Sin embargo, alrededor del 20 % de los casos se presentan en otras localizaciones anatómicas y solo el 2 % tiene afectación del tracto respiratorio superior. Se presenta el caso de una mujer de 75 años, reconsultante al servicio de otorrinolaringología por epistaxis, lesiones postillosas en cavidad nasal y hallazgo de masa nasal. Posterior a la resección quirúrgica de la lesión, se logró la comprobación microbiológica de infección por M. tuberculosis. Se realizan estudios para descartar compromiso pulmonar y de otras localizaciones. Posterior al inicio de tratamiento antituberculoso se logró resolución completa de la lesión y no recurrencia de los síntomas. Las formas extrapulmonares de la infección por M. tuberculosis y, en especial las que afectan la región de la cabeza y el cuello, requieren un alto índice de sospecha para su diagnóstico. Los métodos de diagnóstico como la prueba de PCR y los cultivos de tejidos permiten un óptimo inicio del manejo médico de acuerdo con la epidemiología local y las condiciones del paciente.

Tuberculosis is still a global public health burden. Infection caused by the bacillus Mycobacterium tuberculosis (M. Tuberculosis) manifests mainly in the lungs. However, around 20 % of cases occur in other anatomical locations and only 2 % have upper respiratory tract involvement. We present the case of a 75-year-old female patient, who returned to the otorhinolaryngology service due to epistaxis and postillomous lesions in the nasal cavity with a finding of a nasal mass. After surgical resection of the lesion, microbiological confirmation of M. tuberculosis infection is achieved. Studies are performed to rule-out lung involvement, as well as other locations. After the initiation of tuberculosis treatment, complete resolution of the lesion and no recurrence of symptoms is documented. Extrapulmonary forms of M. tuberculosis infection, and especially those involving the head and neck region, require a high index of suspicion for their diagnosis. Diagnostic methods such as PCR testing and tissue cultures allow optimal initiation of medical management according to local epidemiology and patient conditions.

A tuberculose ainda é um problema de saúde pública global. A infecção causada pelo Mycobacterium tuberculoses manifesta-se principalmente nos pulmões. Entretanto, cerca de 20% dos casos ocorrem em outras localizações anatômicas e apenas 2% apresentam comprometimento do trato respiratório superior. É apresentado o caso de uma mulher de 75 anos que retornou ao serviço de otorrinolaringologia por quadro de epistaxe, lesões com crostas em cavidade nasal e descoberta de massa nasal. Após ressecção cirúrgica da lesão, foi realizada verificação microbiológica de infecção por M. tuberculoses. Estudos são realizados para descartar envolvimento pulmonar e otras localizações. Após início do tratamento antituberculoso, houve resolução completa dalesão e não houve recidiva dos sintomas. As formas extrapulmonares da infecção por M. tuberculoses, especialmente aquelas que acometem a região de cabeça e pescoço, requerem alto índice de suspeita para diagnóstico. Métodos de diagnóstico, como testes de PCR e culturas de tecidos, permitem o início ideal do tratamento médico de acordó com a epidemiologia local e as condições do paciente.

Prokaryotic expression and functional analysis of molecular chaperone Acr2 protein of Mycobacterium tuberculosis / 中国生物制品学杂志

@#Objective To express the molecular chaperone Acr2 protein of Mycobacterium tuberculosis(Mtb)in E.coli and analyze the function. Methods The recombinant plasmid pET-28a-Acr2 was transformed into competent E. coli BL21(DE3),and induced by IPTG. The expressed His-Acr2 protein was purified by Ni-NTA chromatography and SuperdexTM200 10/300 GL gel filtration chromatography to obtain Acr2 protein. The Acr2 protein was refolded by spontaneous refolding and reassembly after thermal denaturation(100 ℃ for 15 min)and chemical denaturation(8 mol/L urea,37 ℃ for 4 h).The secondary structure of Acr2 protein before and after denaturation-renaturation was detected by circular dichroism spectroscopy and non-denaturing SDS-PAGE,and the molecular chaperone function of Acr2 protein in vitro was detected by substrate binding assay. Results The purified Acr2 protein had the relative molecular mass of about 232 000,the purity of over 90%,and the concentration of about 2 mg/mL,which recovered its natural secondary structure after denaturationrenaturation,and formed stable complexes with the denatured malate dehydrogenase(MDH)at 48 ℃. Conclusion The Acr2protein can restore its natural molecular conformation with molecular chaperone activity in vitro after denaturation-renaturation treatment,providing a new strategy for the preparation of Mtb protein antigen with natural activity.

Development and verification of a reversed phase high-performance liquid chromatography method for purity determination of recombinant Mycobacterium tuberculosis Ag85b protein stock solution / 中国生物制品学杂志

@#Objective To develop and verify a reversed phase high-performance liquid chromatography method for the determination of the purity of recombinant Mycobacterium tuberculosis(Mtb)Ag85b protein stock solution.Methods Fourfactor,three-level orthogonal test was designed,with the area,trailing factor,peak area and peak area RSD as the evaluation indexes to explore the optimal detection conditions. The methodology verification of specificity,linear range,precision and durability was conducted in accordance with the general principles of Chinese Pharmacopoeia(Volume Ⅳ,2020 edition)9101.Results The results of all the evaluation indexes were good when the elution ratio of organic phase was30% ～ 95%,the detection temperature was 35 ℃,the sample volume was 3 μg,and the elution time of 95% organic phase was 15 min. The method had the linear correlation coefficient(R2)of 0. 998 5,the linear range of 1. 8 ～ 4. 2 μg,the reproducibility RSD of 0. 01%,and the intermediate precision RSD of 0. 16%,with good durability under slight changes of column temperature and flow rate.Conclusion The reversed phase high-performance liquid chromatography method for the purity determination of recombinant Mtb Ag85b protein stock solution was developed,which has good specificity,precision and durability,and can be used for the quality control of recombinant Mtb Ag85b protein stock solution.

Guideline for clinical diagnosis and treatment of tuberculosis in kidney transplant recipients in China (2023 edition) / 器官移植

This guideline aims to provide comprehensive and practical guidance for clinical management of tuberculosis in kidney transplant recipients. First, it summarizes the particularity of tuberculosis in kidney transplant recipients, and highlights the high incidence and diverse clinical manifestations. To better understand the patients' conditions, relevant assessment of tuberculosis is recommended before kidney transplantation. Extensive attention should be paid to the monitoring of tuberculosis after kidney transplantation. Regarding the diagnosis, the guideline explicitly introduces common diagnostic approaches for tuberculosis, and evaluates the applicability in kidney transplant recipients. After the diagnosis is confirmed, it discusses how to balance the treatment and rejection of tuberculosis under the background of immunosuppressants, and focuses upon the potential drug interaction. In terms of prevention, it emphasizes the screening of tuberculosis prior to kidney transplantation. This guideline is designed to deepen the understanding of medical staff for tuberculosis management in kidney transplant recipients, promote more effective clinical practice and improve the quality of life of the recipients.